Cargando…
Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
Recently Byrski et al. reported the first-ever breast cancer (BC) study, which specifically selected BRCA1-carriers for the neoadjuvant treatment and used monotherapy by cisplatin instead of conventional schemes. Although the TNM staging of the recruited patients was apparently more favorable than i...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676276/ https://www.ncbi.nlm.nih.gov/pubmed/19379506 http://dx.doi.org/10.1186/1897-4287-7-8 |